# Sergei Tjulandin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sergei-tjulandin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,032 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 54 |
| i10-index | 96 |
| Last Known Institution | Georgetown University |
| OpenAlex ID | https://openalex.org/A5012700479 |
| ORCID iD | https://orcid.org/0000-0001-9807-2229 |
| Works | 347 |

## Researcher papers

- [Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer](https://scholariq.org/papers/phase-iii-trial-of-nanoparticle-albumin-bound-paclitaxel-compared-with/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Testicular diseases and treatments](https://scholariq.org/topics/testicular-diseases-and-treatments-2/)

## Researcher university

- [Georgetown University](https://scholariq.org/institutions/georgetown-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.